ADDI GEORGANTZIS: Open Payments
NPI 1083280317 · ENGLEWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,594 in 19 payments from 8 companies in 2025. Trend: 2023 $79 · 2024 $175 · 2025 $1,594
Consulting: $980Food & beverage: $614
| Company | Payments | Amount |
|---|---|---|
| Genmab U.S., Inc. | 2 | $1,003 |
| Janssen Biotech, Inc. | 6 | $359 |
| Immunocore Limited | 2 | $67 |
| Genentech USA, Inc. | 3 | $58 |
| ABBVIE INC. | 3 | $52 |
| TAIHO ONCOLOGY, INC. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Celgene Corporation | 1 | $17 |
Products named: EPKINLY, RYBREVANT, TECVAYLI, KIMMTRAK, IMBRUVICA, Itovebi, LONSURF, Xospata.
Industry payments across NJ — which companies pay providers there.
